在心力衰竭的临床更新与保存的喷射分数
Chayakrit Krittanawong1, William Michael Britt2, Affan Rizwan3
1Cardiology Division, NYU Langone Health and NYU School of Medicine, New York, NY, USA. chayakrit.krittanawong@va.gov.
Current heart failure reports
|September 3, 2024
概括
保存喷射分数 (HFpEF) 的心力衰竭影响了半数心力衰竭患者. 最近的研究突出了其复杂的病理和管理心脏代谢风险因素和并发病的日益重要的重要性,以有效治疗.
科学领域:
- 心脏病学 心脏病学
- 内部医学 内部医学
- 临床研究 临床研究
背景情况:
- 保存喷射分数 (HFpEF) 的心力衰竭约占心力衰竭病例的50%.
- HFpEF与显著的发病率,死亡率和医疗保健成本有关.
- 与心力衰竭相比,HFpEF的有效治疗选择与降低射出分数的心力衰竭相比仍然不太确立.
研究的目的:
- 为提供心力衰竭与保存喷射分数 (HFpEF) 的临床更新.
- 审查最近的临床试验和关于HFpEF流行病学,病理生理学,诊断和治疗的数据.
- 强调HFpEF心脏代谢干预的最新趋势.
主要方法:
- 审查最近的临床试验和流行病学数据.
- 对HFpEF病理生理学的当前理解进行分析.
- 评估新兴的治疗策略,特别是心脏代谢干预措施.
主要成果:
- HFpEF是一种复杂的,异质的综合征.
- 病原发生涉及异常的能量,增大,细胞信号,炎症,缺血和纤维化.
- 诸如心房动,CKD,高血压,肥胖和CAD等并发症与HFpEF密切相关.
结论:
- 管理HFpEF需要通过药理和非药理手段严格监管并发症.
- 对病原体的新兴见解为新疗法提供了潜在的潜力.
- 心脏代谢干预代表了HFpEF管理的日益增长的趋势.
相关概念视频
Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Heart Failure Drugs: Inotropic Agents
545
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
545
Heart Failure Drugs: β-Blockers
322
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
322
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
404
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
404
Heart Failure Drugs: Diuretics
352
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
352
Ischemic Heart Disease: Overview
1.2K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.2K


